All News

The Food and Drug Administration approved the first PARP inhibitor for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma.

One survivor reflects on life after cancer on "cannoli Monday."

As 2019 comes to a close, take a read through CURE®’s top stories of the year.

One male breast cancer survivor reflects on revolutionary developments from the San Antonio Breast Cancer Symposium.

Sometimes the imperfections in life can bring an unexpected beauty. A famous mystery author explores this idea.

The Food and Drug Administration’s accelerated approval of Padcev offers patients with advanced bladder cancer a potential standard of care.

An improved app sends clinical trials straight to the phone of this patient with breast cancer (and she can forward them right to her doctor).

Take a look back at the top 10 podcasts of 2019 – and be sure to subscribe so you don’t miss an episode in 2020.

If you’ve experienced neuropathy, you know what it entails.

The author uses a well-known story about landing in another country to explain cancer journeys.

A two-time cancer survivor suggests simplifying the holidays when coping with cancer.

Falls are a risk for everyone during slushy winter months, but the risk is especially high for people with cancer. Memorial Sloan Kettering physical therapist Jillian Hobson walks readers through what they can do to minimize the chance of falling.

Men with metastatic castration-sensitive prostate cancer will now have a fourth treatment option to consider.

A male breast cancer survivor examines the invisibility factor in this disease.